Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8 + cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation

Plachouri, Kerasia‐Maria; Weishaupt, Carsten; Metze, Dieter; Evers, Georg; Berdel, Wolfgang E.; Kempf, Werner; Sunderkötter, Cord; Stelljes, Matthias

doi:10.1016/j.jdcr.2017.02.004

Cited by 9 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent analysis of data from 34 patients with PC-AETCL confirms poor prognosis, with a 5-year survival rate of 32% and a median survival of only 12 months (36). Autologous/allogeneic HSCT has shown promising results in several recently published cases (36,37). One of our 2 PC-AETCL patients (case number 3) did not respond well to treatment with bexarotene, methotrexate, local radiotherapy and pegylated liposomal doxorubicin and died of progressive disease and sepsis.…”

Section: Discussionmentioning

confidence: 70%

Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study

Brüggen¹,

Kerl²,

Haralambieva³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

Rare T- or NK-cell lymphomas with cutaneous manifestation may display a highly aggressive clinical course and major diagnostic/therapeutic challenges. This report describes our experiences with different lymphomas of this rare category and the therapeutic options used. This retrospective, descriptive, monocentric, cross-sectional case study, identified 4 rare aggressive T-/NK-cell lymphomas with manifestation in the skin, which were diagnosed in a tertiary care centre over a period of 4 years. Two patients had an Epstein-Barr virus-associated extranodal NK/T-cell lymphoma and 2 patients had a primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. Concomitant extracutaneous involvement was observed in 2 of all 4 patients. Two patients had fulminant disease progression and resistance to chemotherapy. Two patients underwent allogeneic haematopoietic stem cell transplantation, which resulted in one complete remission and one partial remission. This report emphasizes the importance of an early diagnostic work-up and a prompt aggressive therapeutic approach.

show abstract

Section: Discussionmentioning

confidence: 70%

Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study

Brüggen¹,

Kerl²,

Haralambieva³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…However, results are disappointing, with limited success and often rapid recurrence. 4 So far the most promising results were achieved with allogeneic hematopoietic stem cell transplantation with a possible curative option, 5,6 which was not possible in our patient owing to rapid progression after multiagent chemotherapy, age and comorbidity. Our patient initially responded surprisingly well to therapy with anti-PD-1 antibody.…”

mentioning

confidence: 87%

“…In conclusion, anti-PD-1 antibodies present a potential treatment option for CD8 + AECTCL, an entity with otherwise few options. [1][2][3][4][5] In addition, mutations in other genes, such as SLC17A9 6 and SSH1, 7 have been reported in disseminated porokeratosis.…”

mentioning

confidence: 99%

Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma

et al. 2020

View full text Add to dashboard Cite

Figure 1 Clinical manifestations before and after treatment with simvastatin ointment in patient 1. (a) Before treatment, the patient presented porokeratotic lesions on the arms and legs. (b) After 2 months of treatment of the right arm and leg (green frame) with an ointment containing simvastatin the lesions almost disappeared. She noticed the benefit only after the first 3 weeks of treatment. The left side of the body was treated with moisturizer.

show abstract

“…Plachouri et al reported a complete durable remission of a fulminant cutaneous aggressive epidermotropic CD8 + cytotoxic T-cell lymphoma after autologous and allo-HSCT. Because of multiple skin ulcerations and a high risk for severe infectious complications, allo-HSCT was not considered as the first salvage option [ 41 ]. Autologous HSCT has been abandoned and is not anymore recommended in the international guidelines [ 7 ].…”

Section: Bridging Therapies To Allo-hsctmentioning

confidence: 99%

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Dumont

Latour

Ram‐Wolff

et al. 2020

Cancers

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that develop primarily in the skin. They account for almost 80% of primary cutaneous lymphomas. Epidermotropic CTCLs (mycosis fungoides (MF) and Sézary syndrome (SS)) are the most common form of CTCL. The course of the disease ranges from an indolent clinical behavior in early-stage disease to an aggressive evolution in the advanced stages. Advanced-stage disease is defined by the presence of tumors, erythroderma, or significant blood, nodal or visceral involvement. Advanced-stage disease is characterized by frequent disease relapses, refractory disease, a severely impaired quality of life and reduced overall survival. In the last twenty-five years, allogeneic hematopoietic stem cell transplantation (HSCT) has led to prolonged remissions in advanced CTCL, presumably linked to a graft-versus-lymphoma effect and is thus emerging as a potential cure of the disease. However, the high post-transplant relapse rate and severe morbidity and mortality associated with graft-versus-host disease and infections are important issues. Allogeneic HSCT is thus mostly considered in young patients with no comorbidities and an aggressive, advanced-stage CTCL. Allogeneic HSCT gives the best results in patients with a pre-transplant complete remission of the lymphoma. For this reason, one of the challenges is to define the best time to consider allogeneic HSCT in the disease course. Early identification of patients at high risk for progression is important to identify candidates who may benefit from allogeneic HSCT before their disease becomes treatment-refractory. This review describes the role of allogeneic HSCT in CTCL, summarizes the published data and future perspectives in this area.

show abstract

Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8 + cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation

Cited by 9 publications

References 8 publications

Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study

Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study

Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Contact Info

Product

Resources

About